Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2026 09:30 ET | Source: LIfT BioSciences

LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer

Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease contextLIfT BioSciences’...
April 22, 2026 09:00 ET | Source: TheRas, Inc. (d/b/a BBOT)

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development...
April 22, 2026 09:00 ET | Source: Capricor Therapeutics

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today...
April 22, 2026 08:30 ET | Source: BioMedWire

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

AUSTIN, Texas, April 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The biotechnology industry is experiencing a subtle yet meaningful transformation that is redefining how value is...
April 22, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a...
April 22, 2026 08:30 ET | Source: Wave Life Sciences USA, Inc.

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...
April 22, 2026 08:00 ET | Source: Axe Compute Inc

Axe Compute Secures $260 million, Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment

PITTSBURGH, April 22, 2026 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU), a neocloud AI infrastructure platform delivering dedicated enterprise GPU compute capacity at global scale, today...
April 22, 2026 08:00 ET | Source: Humacyte, Inc

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success...
April 22, 2026 08:00 ET | Source: Neurona Therapeutics

Neurona Presents Updated Data from Ongoing Clinical Trials of Rezanecel (NRTX-1001) Regenerative Cell Therapy in Mesial Temporal Lobe Epilepsy at 2026 American Academy of Neurology (AAN) Annual Meeting

- UNILATERAL MTLE: Low dose resulted in 89% median disabling seizure reduction in participants with MTS during the 7-12-month primary efficacy evaluation period (N=9), and 100% median disabling...
April 22, 2026 08:00 ET | Source: Cloudbreak Pharma, Inc.

Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026

MKIs uniquely block multiple receptor tyrosine kinases (RTKs) simultaneously, addressing the inflammatory, vascular, and fibrotic causes of serious, underserved front-of-the-eye diseases Lead MKI...